Roche (RHHBY) announced that the European Commission, EC, has approved Columvi in combination with gemcitabine and oxaliplatin for the ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on Roche Holding AG (RHHVF – Research Report), with a price target ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

After community's mixed reaction to rubber worker logo unveiled in 2023, Akron wants to involve residents in decision on next iteration.

The Merkel cell carcinoma market is poised for steady growth, with a strong CAGR projected from 2024 to 2034. This expansion across the 7MM will be driven by the launch of innovative therapies ...

DelveInsight's Merkel Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, Merkel cell carcinoma emerging drugs, market share of individual ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

Global drugmakers' stocks dropped across the board on Wednesday after U.S. President Donald Trump reiterated plans for a ...